Trial · NCT00837902
Genetic Determinants of Response to Beta Blockade
NCT00837902, Not applicable, Completed, Vanderbilt University; results first posted 2018-11-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Genetic Determinants of Response to Beta Blockade. Trials, record NCT00837902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00837902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Genetic Determinants of Response to Beta Blockade
- NCT number
- NCT00837902
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 154 participants, actual
- Lead sponsor
- Vanderbilt University
- Conditions
- Healthy
- Interventions
- Atenolol (β-blocker)
- First posted
- 2009-02-06
- Last updated
- 2018-11-30
- Results first posted
- 2018-11-30
- Limitations and caveats
We cannot extrapolate our results to subjects substantially different from our study group, such as elderly subjects, cardiac patients, or patients on on chronic beta-blocker therapy, or disease states such as heart failure.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction in Heart Rate | 2 exercise periods of 6 minutes each. 6 minutes of exercise before taking atenolol, and 6 minutes of exercise starting 2.5 hours after taking 25 mg of atenolol (2.5 hours + 6 minutes) | Reduction in heart rate based upon genotype while exercising. Participants exercised on a recumbent bike for 2 minutes at 25W, 2 minutes at 50W, and 2 minutes at 75W twice, once before taking atenolol, and once 2.5 hours after oral administration of 25 mg of atenolol. Data points represent unadjusted mean reduction in heart rate in the 3 genotype groups. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Reduction in Heart Rate | 2 exercise periods of 6 minutes each. 6 minutes of exercise before taking atenolol, and 6 minutes of exercise starting 2.5 hours after taking 25 mg of atenolol (2.5 hours + 6 minutes) | There are 3 genotypes for GRK5, GLN/GLN, GLN/LEU, and LEU/LEU. A priori analysis plan was to compare reduction in heart rate among the 3 genotypes.. | beats per minute | MEAN |
Source ClinicalTrials.gov
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Reduction in Heart Rate | GLN/GLN | 0, baseline | 7.9 | Standard Deviation 7 | beats per minute |
| Reduction in Heart Rate | GLN/LEU | 0, baseline | 6 | Standard Deviation 5.9 | beats per minute |
| Reduction in Heart Rate | LEU/LEU | 0, baseline | 3.3 | Standard Deviation 5.4 | beats per minute |
| Reduction in Heart Rate | GLN/GLN | 2 minutes from baseline, 2 minutes exercise at 25W | 9.6 | Standard Deviation 8.2 | beats per minute |
| Reduction in Heart Rate | GLN/LEU | 2 minutes from baseline, 2 minutes exercise at 25W | 8.4 | Standard Deviation 7.7 | beats per minute |
| Reduction in Heart Rate | LEU/LEU | 2 minutes from baseline, 2 minutes exercise at 25W | 7.4 | Standard Deviation 4.4 | beats per minute |
| Reduction in Heart Rate | GLN/GLN | 4 minutes from baseline, 2 minutes exercise at 50W | 11.7 | Standard Deviation 7 | beats per minute |
| Reduction in Heart Rate | GLN/LEU | 4 minutes from baseline, 2 minutes exercise at 50W | 10.9 | Standard Deviation 7.2 | beats per minute |
| Reduction in Heart Rate | LEU/LEU | 4 minutes from baseline, 2 minutes exercise at 50W | 9.1 | Standard Deviation 3.4 | beats per minute |
| Reduction in Heart Rate | GLN/GLN | 6 minutes from baseline, 2 minutes exercise at 75W | 14 | Standard Deviation 8 | beats per minute |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | White Participants--Atenolol | 85 | |
| Overall Study | STARTED | Black Participants-Atenolol | 69 | |
| Overall Study | COMPLETED | White Participants--Atenolol | 85 | |
| Overall Study | COMPLETED | Black Participants-Atenolol | 69 | |
| Overall Study | NOT COMPLETED | White Participants--Atenolol | 0 | |
| Overall Study | NOT COMPLETED | Black Participants-Atenolol | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | White Participants--Atenolol | 0 | 85 |
| Total, all-cause mortality | Black Participants-Atenolol | 0 | 69 |
| Total, other adverse events | White Participants--Atenolol | 0 | 85 |
| Total, other adverse events | Black Participants-Atenolol | 0 | 69 |
| Total, serious adverse events | White Participants--Atenolol | 0 | 85 |
| Total, serious adverse events | Black Participants-Atenolol | 0 | 69 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 19842931 | RESULT |
Source PubMed
Grants3
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| P01HL056693 | Autonomic Cardiovascular Regulation | BIAGGIONI, ITALO | VANDERBILT UNIVERSITY MEDICAL CENTER | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 1997 to 2016 | NIH RePORTER |
| UL1RR024975 | The Vanderbilt Institute for Clinical and Translational Research (VICTR) UL1 | BERNARD, GORDON RAPHAEL | VANDERBILT UNIVERSITY | NATIONAL CENTER FOR RESEARCH RESOURCES | 2007 to 2011 | NIH RePORTER |
| U01HL065962 | Pharmacogenomics of Arrhythmia Therapy | RODEN, DAN M | VANDERBILT UNIVERSITY | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2001 to 2009 | NIH RePORTER |
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| White Participants--Atenolol vs Black Participants-Atenolol: deaths from any cause | Trial comparisons |
| White Participants--Atenolol vs Black Participants-Atenolol: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00837902
GET https://conductscience.org/api/trials/v1/NCT00837902/registered